hotspot -WSS

hotspot

author：leisure time 2025-09-06 02:16:15 - browse：9643

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Ohioans vote in high

hotspot

WSS

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Lessons Learned: This is why you network to find that industry job you want

Sage's campaign to raise awareness of postpartum depression hits a nerve

Why failed clinical trials don’t always spell doom for a new drug

Police still searching for prisoner who escaped from NYC hospital

hotspot

hotspot

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Choosing scientific sides in the fight against Alzheimer's

Affirmative action in medical school literally saved lives

Wegovy trial has doctors encouraged over new possibilities

How one medical school became remarkably diverse

Emergent cuts jobs, executive role in business shake

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Police still searching for prisoner who escaped from NYC hospital

Medical leaders decry Supreme Court decision on affirmative action

Wegovy trial has doctors encouraged over new possibilities

Wikipedia

Why failed clinical trials don’t always spell doom for a new drug

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

FTX founder Sam Bankman

‘The Bear’ and hospitality in hospitals

How to use technology to prevent future drug shortages

NIH trials fail to test meaningful long Covid therapies, experts say

focus

hotspot

focus

hotspot